Formats
  1. Journal Article (66975)
  2. Meeting Abstract (33621)
  3. Book Section (5116)
  4. Review (3781)
  5. Editorial (2185)
  6. Conference Paper (1531)
  7. Correspondence (669)
  8. Guidelines (666)
  9. Research Letter (554)
  10. Book Whole (345)
  11. Miscellaneous (340)
Groups
  1. Department of Medicine (39123)
  2. GSK Faculty (22500)
  3. Solid Tumor Oncology Division (22113)
  4. Surgery (21304)
  5. Survivorship Research (15795)
  6. Sloan Kettering Institute Faculty (15665)

More Groups

People
  1. Marc Ladanyi (1328)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1053)

More People

Years
  1. 2026 (1)
  2. 2025 (2315)
  3. 2024 (5382)
  4. 2023 (5808)
  5. 2022 (6169)
  6. 2021 (5720)

More Years

Publications
  1. Journal of Clinical Oncology (8596)
  2. Blood (4954)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2614)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1814)

More Publications

Publishers
  1. Elsevier Inc. (13867)
  2. American Society of Clinical Oncology (9180)
  3. Springer (7199)
  4. Nature Publishing Group (6392)
  5. American Association for Cancer Research (6014)
  6. Elsevier Science, Inc. (5526)

More Publishers

Results (115783)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma
    Meeting Abstract

    Rubinstein, M. M.; Caird, I.; Zhou, Q.; Iasonos, A.; Friedman, C. F.; Cadoo, K. A.; Konner, J. A.; O'Cearbhaill, R. E.; Tew, W. P.; Zamarin, D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus ), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results
    Meeting Abstract

    Rugo, H. S.; Borrego, M. R.; Chia, S. K. L.; Juric, D.; Turner, N. C.; Drullinsky, P.; Lerebours, F.; Bianchi, G. V.; Nienstedt, C. C.; Ridolfi, A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Association of pancreatic cancer stem cells with tumor stroma type
    Meeting Abstract

    Sahin, I. H.; Askan, G.; Chou, J. F.; Capanu, M.; Yu, K. H.; Basturk, O.; Iacobuzio-Donahue, C. A.; O'Reilly, E. M.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Prediagnosis cardiovascular risk and subsequent myocardial infarction (Ml) among lymphoma survivors
    Meeting Abstract

    Salz, T.; Zabor, E. C.; de Nully Brown, P.; Dalton, S. O.; Raghunathan, N. J.; Matasar, M. J.; Steingart, R.; Hjalgrim, H.; Specht, L.; Oeffinger, K. C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC)
    Meeting Abstract

    Sammons, S.; Tan, T. J. Y.; Traina, T. A.; Kim, S. B.; Im, Y. H.; Bachelder, C.; Marcom, P. K.; Dent, R. A.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • DNA damage response pathway alterations and clinical outcome in leiomyosarcoma
    Meeting Abstract

    Rosenbaum, E.; Jonsson, P.; Seier, K.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Qin, L. X.; Hensley, M. L.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Somatic mutational profile of Merkel cell carcinoma treated with immune checkpoint blockade: Preliminary results from a planned multiplatform analysis
    Meeting Abstract

    Rosenbaum, E.; Kelly, C. M.; Barker, C. A.; Adamson, T.; Kiesler, H.; Hundal, J.; Paul, A. J.; McLellan, M. D.; Walker, J.; Tap, W. D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase Ill trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma
    Meeting Abstract

    Rosenberg, J. E.; Ballman, K. V.; Halabi, S.; Watt, C.; Hahn, O. M.; Steen, P. D.; Dreicer, R.; Flaig, T. W.; Stadler, W. M.; Sweeney, C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase 1 study of CA-4948, a novel inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) in patients (pts) with r/r non-Hodgkin lymphoma
    Meeting Abstract

    Rosenthal, A. C.; Tun, H. W.; Younes, A.; Nowakowski, G. S.; Lunning, M. A.; Patel, K.; Landsburg, D. J.; Martell, R. E.; Leslie, L. A.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO)
    Meeting Abstract

    Rousseau, B.; Boukerma, A. K.; Henriques, J.; Cohen, R.; Lucidarme, O.; Borg, C.; Tournigand, C.; Kim, S. C. H.; Bachet, J. B.; Mazard, T.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save